Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

6.83
BATS BZX Real-Time Price
As of 11:09am ET
 +0.74 / +12.15%
Today’s Change
1.51
Today|||52-Week Range
8.04
+234.80%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$544.1M

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Other institutional46.23%
Mutual fund holders30.20%
Individual stakeholders3.01%

Top Executives

Mark J. EnyedyPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Richard J. GregoryChief Scientific Officer & Executive VP
Anna BerkenblitChief Medical Officer & Vice President
Thomas RyllVice President-Technical Operations